Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 1998

View Archived Issues

InSite Vision highlights recent accomplishments in shareholder update

Pharmacia & Upjohn launches new antidepressant in Germany

Oxford GlycoSciences: six-month highlights

Herbal mixture used for prostate cancer found to have potent estrogenic effects

Siga will collaborate with Ludwig Institute to develop cancer vaccines

New technology useful for identifying protein targets for anti-H. pylori agents

Novel Lp(a)-lowering agents prepared by SKB-Symphar team

Modulators of neurotransmitter function claimed by Hoechst Marion Roussel for depression, PD

Heterocyclic anticoagulants in development at BioChem Pharma

Knoll claims another series of heteroarylsulfonamide compounds for CNS and other disorders

Japanese laboratory synthesizes new antidiabetic agents

Israeli investigators disclose novel series of neuroprotective compounds

Sepracor initiates clinical testing with Prozac isomer

Chinese herbal extract prevents stress and fatigue in preclinical models

Collaborative agreements in the field of asthma signed by SkyePharma and Sepracor

3M launches revolutionary new treatment for external genital and perianal warts in U.K.

BioNumerik publishes preclinical data on BNP-7787 in cancer journal

U.K. launch announced for Evista

Pharming and Genzyme form joint venture to develop enzyme for Pompe's disease

International research team elucidates role of ubiquitin pathway in Parkinson's disease

Phase I trials to begin with vomeropherin compound for PMS

Update on development of ViroPharma's pleconaril

United Therapeutics reports successful completion of pilot study in PVD

New compound reported in clinical development at Lilly

NeXstar reorganizes into two separate companies

United Biomedical's B4 antibody holds promise for postexposure prophylaxis of HIV infection

Ampakine compounds receive further patent protection; update on progress of second-generation drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.